Health
Related: About this forumFDA agrees to review Moderna mRNA flu vaccine in dramatic reversal
The U.S. Food and Drug Administration will review a messenger RNA (mRNA) flu vaccine for approval, according to its maker, Moderna. The decision is a dramatic U-turn for the agency, which, only about a week ago, had publicly rejected Modernas application to get the shot reviewed.
When it initially rejected the application, the FDA had said Modernas clinical trials were lacking. On Wednesday, Moderna said it had made modifications to its application. While the reversal has been welcomed by the vaccine maker and public health experts alike, the incident has been the latest instance of the Trump administration undermining vaccine science. Secretary of Health and Human Services Robert F. Kennedy, Jr., whose department has jurisdiction over the FDA, is a noted vaccine skeptic who has repeatedly criticized mRNA COVID vaccines.
HHS spokesperson Andrew Nixon said in a statement that the FDA had held discussions with the company, leading to a revised regulatory approach and an amended application, which FDA accepted.
FDA will maintain its high standards during review and potential licensure stages as it does with all products, Nixon said.
William Schaffner, an infectious disease physician and a professor at Vanderbilt University Medical Center, says the FDAs decision to backtrack is good news.
https://www.scientificamerican.com/article/fda-agrees-to-review-moderna-mrna-flu-vaccine-in-dramatic-reversal/
yaesu
(9,160 posts)LetMyPeopleVote
(177,433 posts)Moderna revised its application following the FDA's surprise decision to not review the flu shot.
A bit of good news this morning: FDA reverses course, will review Moderna's mRNA flu vaccine
— Laura Haynesð©âð¬â¾ï¸ð¾ð (@drlaurahaynes.bsky.social) 2026-02-18T14:13:46.545Z
www.nbcnews.com/health/healt...
https://www.nbcnews.com/health/health-news/fda-reverses-course-will-review-modernas-mrna-flu-vaccine-rcna259531
The reversal, which comes just a week after the FDAs surprise decision to not review the companys experimental flu vaccine application, lifted shares of the vaccine maker more than 3% before the bell.
The FDA has accepted Modernas revised approach seeking full approval for the shot for adults aged between 50 and 64, and accelerated approval for those aged 65 and above, the company said, adding that it will also conduct a post-marketing study in older adults.
The mRNA technology used in Modernas and most other Covid shots, credited with saving millions of lives, comes with a shift in the national health policy under Health Secretary Robert F. Kennedy Jr., a long-time anti-vaccine activist who has been particularly critical of mRNA vaccines.
The regulator had defended its initial decision, saying the company should have given a higher-strength vaccine to older patients in the control arm of its trial.